Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial.
Jürgen H ProchaskaClaus JüngerAndreas SchulzNatalie ArnoldFelix MüllerMarc William HeidornRieke BaumkötterDaniela ZahnThomas KoeckSven-Oliver TröbsKarl J LacknerAndreas DaiberHarald BinderSanjiv J ShahTommaso GoriThomas MünzelPhilipp S WildPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2023)
Clinicaltrials.gov, unique identifier: NCT02932436.
Keyphrases
- placebo controlled
- left ventricular
- double blind
- phase iii
- phase ii
- study protocol
- clinical trial
- hypertrophic cardiomyopathy
- healthcare
- phase ii study
- cardiac resynchronization therapy
- heart failure
- acute myocardial infarction
- palliative care
- left atrial
- aortic stenosis
- mitral valve
- quality improvement
- open label
- randomized controlled trial
- blood pressure
- pain management
- affordable care act
- ejection fraction
- radiation therapy
- coronary artery disease
- health insurance